We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-1.78%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$54B
AUM Growth
-$3.2B
(-5.6%)
Cap. Flow
-$865M
Cap. Flow
% of AUM
-1.6%
Top 10 Holdings %
Top 10 Hldgs %
28.71%
Holding
986
New
116
Increased
314
Reduced
359
Closed
149
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hubbell
HUBB
|
+$244M |
| 2 |
Norfolk Southern
NSC
|
+$149M |
| 3 |
Insmed
INSM
|
+$138M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$131M |
| 5 |
Danaher
DHR
|
+$119M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$340M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$339M |
| 3 |
Union Pacific
UNP
|
+$191M |
| 4 |
McDonald's
MCD
|
+$190M |
| 5 |
HES
Hess
HES
|
+$168M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.3% |
| 2 | Healthcare | 14.99% |
| 3 | Financials | 12.56% |
| 4 | Consumer Discretionary | 9.54% |
| 5 | Industrials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Alcon
ALC
$33.9B
| $1.52M | ﹤0.01% |
16,000
-265,020
| -94% | -$23.8M |
|
777
SLB Ltd
SLB
$76.5B
| $1.46M | ﹤0.01% |
35,013
-255,811
| -88% | -$10.5M |
|
778
Talos Energy
TALO
$2.35B
| $1.46M | ﹤0.01% |
150,000
-662,348
| -82% | -$6.28M |
|
779
AN2 Therapeutics
ANTX
$219M
| $1.36M | ﹤0.01% |
1,000,000
+687,385
| +220% | +$865K |
|
780
Shoals Technologies Group
SHLS
$1.45B
| $1.33M | ﹤0.01% |
400,000
| – | – |
|
781
Moog Inc Class A
MOG.A
$13B
| $1.31M | ﹤0.01% |
7,553
| – | – |
|
782
Sutro Biopharma
STRO
$400M
| $1.3M | ﹤0.01% |
200,000
| – | – |
|
783
Alignment Healthcare
ALHC
$2.78B
| $1.29M | ﹤0.01% |
69,497
+35,000
| +101% | +$522K |
|
784
Liberty Energy
LBRT
$3.27B
| $1.27M | ﹤0.01% |
80,000
| – | – |
|
785
Albemarle
ALB
$14.8B
| $1.24M | ﹤0.01% |
17,279
-42,500
| -71% | -$3.46M |
|
786
Werner Enterprises
WERN
$2.21B
| $1.19M | ﹤0.01% |
40,545
| – | – |
|
787
Invesco
IVZ
$14B
| $1.15M | ﹤0.01% |
+75,941
| New | +$1.3M |
|
|
CBIO
788
Crescent Biopharma
CBIO
$610M
| $1.07M | ﹤0.01% |
50,912
| – | – |
|
789
Biomea Fusion
BMEA
$90.4M
| $1.06M | ﹤0.01% |
500,000
| – | – |
|
790
HealthEquity
HQY
$8.65B
| $1.06M | ﹤0.01% |
12,000
+4,000
| +50% | +$410K |
|
791
CNO Financial Group
CNO
$5.14B
| $1.04M | ﹤0.01% |
+25,000
| New | +$998K |
|
792
Surrozen
SRZN
$251M
| $1.03M | ﹤0.01% |
88,653
+24,000
| +37% | +$279K |
|
793
DexCom
DXCM
$31.3B
| $1.03M | ﹤0.01% |
15,121
-540,000
| -97% | -$44.1M |
|
|
IMA
794
ImageneBio Inc
IMA
$64M
| $1.02M | ﹤0.01% |
66,667
| – | – |
|
795
Alexandria Real Estate Equities
ARE
$8.34B
| $981K | ﹤0.01% |
+10,600
| New | +$1.04M |
|
|
APLT
796
DELISTED
Applied Therapeutics
APLT
| $959K | ﹤0.01% |
1,961,629
| – | – |
|
797
AngioDynamics
ANGO
$625M
| $939K | ﹤0.01% |
+100,000
| New | +$1.05M |
|
798
Match Group
MTCH
$8.54B
| $908K | ﹤0.01% |
29,116
-5,500
| -16% | -$180K |
|
799
Carnival Corporation Ltd
CCL
$39.4B
| $900K | ﹤0.01% |
46,084
-924,416
| -95% | -$22M |
|
800
Trinity Industries
TRN
$2.47B
| $841K | ﹤0.01% |
+29,978
| New | +$1M |
|
Similar funds
Adage Capital Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Adage Capital Partners held 986 positions worth $54B, down 5.6% from $57.2B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners's Q1 2025 filing shows 116 new, 314 increased, 359 reduced and 149 closed positions. Its largest new stake was Diamondback Energy: 485,503 shares worth $77.6M. The largest sale was Royalty Pharma, an estimated $340M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2025 buy was Diamondback Energy: 485,503 shares worth $77.6M.
- Adage Capital Partners added most to Hubbell in Q1 2025, an estimated $244M increase.
- Adage Capital Partners's biggest Q1 2025 reduction was Royalty Pharma, cutting an estimated $340M.
- Adage Capital Partners fully exited Geron in Q1 2025, selling an estimated $77.2M.
- Adage Capital Partners's ten largest holdings make up 29% of its $54B portfolio in Q1 2025.
- Adage Capital Partners opened 116 new positions and closed 149 in Q1 2025.
- Adage Capital Partners's portfolio value fell 5.6% quarter-over-quarter to $54B.
Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.